Tryptamine Therapeutics (ASX:TYP) has confirmed it’s wrapped up its first-ever IV psilocin injections in 11 patients being used to establish baseline dosage data. The company’s Phase 1b study saw patients administered the psychoactive byproduct via IV over 2-and-a-half hours. All patients were discharged without incident. This latest activity was established not to assess outcomes necessarily but to establish baseline safety data for further trials investigating the effects on the drug on the mind and subsequent outcomes post-administration. The company is particularly keen to figure out what …
